United Neuroscience Announces Presentation at the 2018 Alzheimer's Association International Conference® (AAIC®)

DUBLIN, July 18, 2018 /PRNewswire/ -- United Neuroscience, Ltd., (UNS), a clinical stage biotech company focused on the treatment of Alzheimer's, announced today that the company will present at the upcoming Alzheimer's Association International Conference (AAIC) being held July 22-26, 2018, in Chicago. AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research.

"At United Neuroscience, we envision a world where vaccines are used to treat and ultimately prevent Alzheimer's," said Ajay Verma, M.D., Ph.D., CMO of United Neuroscience. "We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry's leading endobody vaccine technology. Our presence at AAIC this year demonstrates our commitment to transforming the lives of all patients and families affected by Alzheimer's."

Poster Presentation Details:

Title: Baseline Characteristics for Patients with Mild Alzheimer's Disease Enrolled in the Phase IIa Trial of Active Immunotherapeutic Vaccine UB-311
Date: July 22, 2018
Time: 9:30 am ? 4:15 pm CDT
Location: Hall - F1, McCormick Place, Chicago
Abstract Number: P1-037

About AAIC

The Alzheimer's Association International Conference® (AAIC®) is the largest and most influential international meeting dedicated to advancing dementia science. The Conference assembles the world's leading researchers, clinicians and the care research community to communicate discoveries that will lead to methods of prevention and treatment for Alzheimer's disease. For more information about AAIC, please visit www.alz.org/aaic.

About United Neuroscience

United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of best-in-class immunotherapeutics for the brain. A global company headquartered in Dublin, Ireland, with operations in Taiwan and the United States, UNS was founded to address the social and economic burden of Alzheimer's and other neurodegenerative diseases and seeks to rapidly advance candidates into and through clinical trials with the goal of delivering breakthrough treatments to patients. For more information please visit www.unitedneuroscience.com. Follow UNS on Twitter at https://twitter.com/UNSTechBio and on LinkedIn at https://www.linkedin.com/company/unitedneuroscience.

Media Contacts

David Schull or Brittanie Dougherty
Russo Partners, LLC
(212) 845-4271
(646) 942-5634
[email protected]
[email protected]

SOURCE United Neuroscience, Ltd.